CAS: 5470-22-4; 4-Chloropicolinic Acid

相似化合物

19235-89-3 24484-93-3 63071-10-3

上下游产品

4-chIoro-2-methylpyridine 4-chloro-pyridine-2-carbonyl chloride 4,4'-dichloro-2,2'-bipyridine 2-picolinic acid hydr°Chloride 4-hydroxypyridine-2-carboxylic acid tert-butyl (4-chloropyridin-2-yl) carbamate 4-chloro-pyridine-2-carbonyl chloride 2-Picolinic acid

2-吡啶甲酸置于氯化亚砜,Sodium Hydroxide体系中,化学反应 97.0H,反应生成 4-氯-2-吡啶甲酸
参考文献:Dual-Action Inhibitors Of Hif Prolyl Hydroxylases That Induce Binding Of A Second Iron Ion
标题:Dual-Action Inhibitors Of Hif Prolyl Hydroxylases That Induce Binding Of A Second Iron Ion
摘要:翻译结果: 对缺氧诱导因子(hif)脯氨酰羟化酶(phd或egln酶)的抑制在治疗贫血和缺血相关疾病方面备受关注.大多数phd抑制剂通过结合单个亚铁离子并与2-氧代戊二酸(2Og)共底物竞争结合phd活性位点来发挥作用.非特异性铁螯合剂也能在体外和细胞内抑制phd.我们报告了双作用phd抑制剂的鉴定,这些抑制剂不仅与活性位点的铁结合,还能诱导在活性位点上结合第二个铁离子.通过对小分子铁络合物的分析并在非变性蛋白质谱法中评估phd2.铁.抑制剂的比例后,鉴定出某些二酰基联氨为诱导第二个铁离子结合的phd2抑制剂.有些化合物被证明能抑制人类肝癌和肾癌细胞系中的hif羟化酶.
DOI:10.1039/c2Ob26648B

专利信息

专利号:US-3933830-A
优先权日:1974-09-10
标 题 :Process for the synthesis of 4-(2-pyridylamido ethyl) piperidines
发明人：BARTH WAYNE E; KUHLA DONALD E
权利人:PFIZER
摘要:Disclosed herein is an improved process for the preparation of known hypoglycemic piperidinesulfamylureas of the structure ##EQU1## wherein R is selected from the group consisting of 3-(2-methoxy)pyridyl, 3-(2-ethoxy)pyridyl and 2-(4-chloro)pyridyl and R' is selected from the group consisting of bicyclo[2.2.1]hept-5-en-2-yl-endo-methyl, bicyclo[2.2.1]hept-2-yl-endo-methyl, 7-oxabicyclo[2.2.1]hept-2-yl-methyl, 1-adamantyl and cycloalkyl having from five to eight carbon atoms. n Said process comprises contacting 4-(2-pyridyl-amidoethyl) piperidine of the structure ##EQU2## with substantially one equivalent of sulfamide thereby exclusively sulfonating the piperidine nitrogen atom. Said 4-(2-pyridylamidoethyl)piperidines from the corresponding 4-(2-pyridylamidoethyl) pyridines by selectively activating the more basic nitrogen atom of said pyridine compound either by N-alkylation or by contact with acid and then exclusively reducing the activated pyridine ring with either hydrogen alone or in combination with a metal hydride. Said 4-(2-pyridylamidoethyl)pyridines are produced by contacting 4-(2-aminoethyl)pyridine with a pyridyl acid chloride of the formula R(C=O)Cl. The piperidine sulfonamides produced by the process of the instant invention are converted to the desired hypoglycemic agent by methods well-known to those skilled in the art. n The 4-(2-pyridylamidoethyl)pyridines and piperidines of the instant invention are themselves novel compounds useful as intermediates in the synthesis of piperidine sulfamylurea hypoglycemic agents.

专利号:US-2025115629-A1
优先权日:2021-03-18
标 题 :Chiral synthons for the synthesis of chiral phosphorothioates
发明人：ZHANG YONGDA; WU LINGLIN
权利人:BOEHRINGER INGELHEIM INT
摘要:This invention relates to compounds of Formula (I) useful as synthons for a general synthetic method for making chiral phosphorothioates, to their preparation and to their use in a robust large scale process for making P-chiral phosphorothioates.

专利号:US-9676783-B2
优先权日:2008-10-22
标 题:Method of treatment using substituted pyrazolo[1,5-A] pyrimidine compounds
发明人：HAAS JULIA; ANDREWS STEVEN W; JIANG YUTONG; ZHANG GAN
权利人:ARRAY BIOPHARMA INC
摘要:Compounds useful in the synthesis of compounds for treating pain, cancer, inflammation, neurodegenerative disease or Typanosoma cruzi infection in a mammal.

专利号:EP-3686190-A1
优先权日:2013-07-11
标 题 :Synthesis of therapeutically active compounds

专利号:WO-2022194924-A1
优先权日:2021-03-18
标 题:Chiral synthons for the synthesis of chiral phosphorothioates

专利号:US-12304912-B2
优先权日:2020-07-28
标 题 :Fused bicyclic RAF inhibitors and methods for use thereof
发明人：BELFIELD ANDREW; JONES CLIFFORD DAVID; MARGATHE JEAN-FRANÇOIS; COLLETTO CHIARA
权利人:JAZZ PHARMACEUTICALS IRELAND LTD
摘要:The present disclosure generally relates to improved synthesis of fused bicyclic Raf inhibitors of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof. The disclosure also relates to method of using the compound of formula (I), (I-A), (I-B), (II), or (III), or a pharmaceutically acceptable salt, tautomer, or stereoisomer thereof, for treating diseases such as cancer, including colorectal cancer.